亞太地區分子腫瘤診斷市場（按癌症類型、最終用戶和國家分類）分析與預測（2024 年至 2033 年）

預計2024年亞太地區分子腫瘤診斷市場規模將達5.136億美元。

預計到2033年，該市場規模將達到15.42億美元，複合年成長率為12.99%。數位PCR、液態切片和次世代定序（NGS）是推動亞太地區分子癌症診斷市場爆炸性成長的關鍵技術驅動力。中國、印度和日本等國家的癌症發生率上升，推動了人們對更早發現、更精準治療方法方案以及最終改善患者預後的需求。

然而，一些地區性障礙阻礙了該技術的廣泛應用。先進分子診斷的高成本仍然是一大障礙，尤其是在東南亞等醫療資源匱乏的市場。此外，該地區許多地區缺乏能夠運作先進診斷系統並解讀大量基因組數據的合格專業人員。

儘管面臨這些障礙，亞太市場仍在持續成長。創新正在加速，生物技術、製藥、診斷試劑製造商和學術機構之間的合作正在將分子工具整合到常規腫瘤學工作流程中。為了充分實現精準癌症診斷的前景，相關人員需要規範報銷流程，透過本地生產和規模化生產降低檢測成本，並資助培訓項目，以提高各醫療體系臨床醫生的基因組學素養。

市場介紹

隨著中國、印度、日本和東南亞的醫療體系更加重視精準醫療，亞太地區的癌症分子診斷市場預計將快速成長。分子檢測，尤其是次世代定序(NGS)、數位 PCR 和液態切片，的使用正在增加，因為它們可以比傳統技術更準確、更早地識別癌症相關的基因變異。這些尖端儀器的需求是由於大腸癌、肺癌和乳癌發生率的上升，以及患者和醫生意識的提高。國家基因組計劃、伴隨診斷建議以及公共和私人對實驗室基礎設施的投資也推動了臨床應用。高昂的測試價格、脫節的監管程序以及合格的生物資訊學家和分子技術人員的短缺，尤其是在低收入地區，仍然是主要障礙。

為了克服這些障礙，產業相關人員正在建立策略聯盟，提高本地生產能力，並實施培訓計畫以發展技術專長。同時，自動化、高通量平台的引進也加快了流程並縮短了交貨時間。未來，人工智慧驅動的生物資訊學、擴大的保險覆蓋範圍以及更強大的數據安全框架的結合，對於推動該行業的長期擴張至關重要。透過在各種醫療環境中提供更個人化和高效的癌症治療，預計到2030年，亞太地區分子腫瘤診斷市場將在全球精準腫瘤學市場中佔據重要佔有率。

市場區隔

細分一：按癌症類型

• 固體癌
• 骨髓惡性腫瘤

細分 2：按最終用戶

• 醫院和診斷中心
• 參考實驗室
• 製藥和生物技術公司
• 學術和研究機構

第 3 部分：按地區

• 亞太地區－日本、中國、印度、韓國、澳洲、世界其他地區

亞太地區分子腫瘤診斷市場趨勢、促進因素與挑戰：

市場趨勢

• 技術進步：次世代定序儀(NGS)、數位 PCR 和液態切片(ctDNA/ctC) 無創即時癌症監測的快速應用
• 整合與夥伴關係：活性化將重塑競爭格局，大型實驗室和診斷機構將收購或與領先平台合作。
• 伴隨診斷整合：受日本和澳洲等主要市場監管指南不斷演變的推動，採用伴隨診斷檢測來匹配患者和標靶治療正在日益增多。
• 自動化和高通量平台：為了提高效率和試樣處理通量，臨床和研究實驗室都在採用自動化系統。

市場促進因素

• 癌症發生率上升：中國、印度、日本和東南亞的乳癌、肺癌和大腸癌發生率急劇上升，刺激了對精準診斷的需求。
• 推動精準醫療：個人化腫瘤學正在成為策略轉變，付款人和提供者都投資於基因型指導的治療途徑。
• 政府和公私合作舉措：進行基礎設施擴建的國家計畫和夥伴關係，例如基因組學使命和伴隨診斷指南。
• 醫療基礎設施投資：資金流入實驗室升級、生物技術研發和專門的癌症中心將增強當地的能力。

市場挑戰

• 檢測成本高：先進的分子檢測仍然價格昂貴，限制了其在低收入亞太市場的採用。
• 監管複雜性：各國核准途徑分散且不斷變化，導致產品上市延遲。
• 缺乏技術人員：訓練有素的分子技術人員和生物資訊學家的短缺阻礙了更廣泛的臨床部署。
• 資料安全和隱私：處理敏感的基因組和病患資料會引發合規性和網路安全問題。

目錄

執行摘要

第1章 分子腫瘤診斷市場：產業展望

• 全球癌症發生率和盛行率（按癌症類型分類）
  • 亞太地區
• 趨勢：現況與未來影響評估
  • 加強參與企業間的夥伴關係
  • 增加分子腫瘤診斷生態系統中的創新產品發布和監管核准
• 監管狀況
  • 亞太地區的法律要求與框架
• COVID-19 對分子腫瘤診斷市場的影響
• 基於液態生物檢體的分子癌症診斷
• 實驗室測試（LDT）和體外診斷（IVD）
• 伴隨診斷在分子腫瘤診斷市場中的作用
• 市場動態
  • 市場促進因素
  • 市場挑戰
  • 市場機會

第2章 分子腫瘤診斷市場（按地區）

• 區域摘要
• 促進因素和約束因素
• 亞太地區
  • 區域概況
  • 市場成長動力
  • 成長抑制因素
  • 按癌症類型
  • 按最終用戶
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 其他
• 其他地區

3. 分子腫瘤診斷市場競爭基準化分析與公司概況

• 公司簡介
  • Sysmex Corporation

第4章調查方法

This report can be delivered in 2 working days.

Introduction to Asia-Pacific Molecular Oncology Diagnostics Market

The Asia-Pacific molecular oncology diagnostics market was valued at $513.6 million in 2024, and the market is expected to grow with a CAGR of 12.99% and reach $1,542.0 million by 2033. Digital PCR, liquid biopsy, and next-generation sequencing (NGS) are the main technological factors propelling the APAC molecular cancer diagnostics market's explosive expansion. The need for earlier detection, more accurate therapy choices, and ultimately improved patient outcomes is being fuelled by the rising incidence of cancer in nations like China, India, and Japan.

However, a number of regional obstacles prevent wider implementation. In markets with smaller healthcare resources, especially in Southeast Asia, the high cost of advanced molecular diagnostics continues to be a significant barrier. Furthermore, in many areas of the region, there is a lack of qualified experts who can run sophisticated diagnostic systems and decipher massive amounts of genomic data.

The APAC market is still growing in spite of these obstacles. Innovation is being accelerated and molecular tools are being incorporated into routine oncology workflows through cooperative efforts between biotech businesses, pharmaceutical companies, diagnostic manufacturers, and academic institutions. Stakeholders must standardise reimbursement practices, reduce test costs through local and scaled production, and fund training initiatives to increase clinician genomic literacy across various healthcare systems if they are to fully realise the promise of precision cancer diagnostics.

Market Introduction

The market for molecular oncology diagnostics in Asia-Pacific (APAC) is expected to grow quickly as healthcare systems in China, India, Japan, and Southeast Asia place a greater emphasis on precision medicine. The use of molecular assays, especially next-generation sequencing (NGS), digital PCR, and liquid biopsy, is growing because they can more precisely and early identify genetic changes linked to cancer than conventional techniques. The demand for these cutting-edge instruments is being driven by the rising prevalence of colorectal, lung, and breast cancers as well as increased patient and physician awareness. Clinical adoption is also being accelerated by national genomics programs, companion diagnostics recommendations, and public and private investments in laboratory infrastructure. High test prices, disjointed regulatory procedures, and a lack of qualified bioinformaticians and molecular technologists, particularly in lower-income regions, continue to be major obstacles.

Industry participants are establishing strategic alliances, increasing locally produced goods, and putting in place training initiatives to develop technological know-how in order to overcome these obstacles. Automated high-throughput platforms are being implemented in the meanwhile to expedite processes and shorten turnaround times. In the future, the combination of AI-powered bioinformatics, increased reimbursement coverage, and more robust data-security frameworks will be essential for promoting long-term industry expansion. By providing more individualised, efficient cancer treatment in a variety of healthcare settings, the APAC molecular oncology diagnostics market is anticipated to take a sizable chunk of the worldwide precision oncology market by 2030.

Market Segmentation:

Segmentation 1: by Cancer Type

• Solid Tumors
• Hematologic Malignancies

Segmentation 2: by End User

• Hospitals and Diagnostic Centers
• Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

Segmentation 3: by Region

• Asia-Pacific - Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific

APAC Molecular Oncology Diagnostics Market Trends, Drivers & Challenges:

Market Trends

• Technological Advancements: Rapid uptake of next generation sequencing (NGS), digital PCR and liquid biopsies (ctDNA/ctC) for non invasive, real time cancer monitoring.
• Consolidation & Partnerships: Increased M&A activity reshaping the competitive landscape, with major lab and diagnostics players acquiring or partnering on advanced platforms.
• Companion Diagnostics Integration: Growing adoption of CDx assays to match patients with targeted therapies, supported by evolving regulatory guidelines in key markets like Japan and Australia.
• Automation & High Throughput Platforms: Deployment of automated systems in both clinical and research labs to boost efficiency and sample throughput.

Market Drivers

• Rising Cancer Incidence: Surging rates of breast, lung and colorectal cancers across China, India, Japan and Southeast Asia fueling demand for precise diagnostics.
• Precision Medicine Push: Strategic shift toward personalized oncology, with payers and providers investing in genotype-guided treatment pathways.
• Government & Public-Private Initiatives: National programs and partnerships underwriting infrastructure expansion, including genomics missions and companion diagnostics guidelines.
• Healthcare Infrastructure Investments: Capital inflows into lab upgrades, biotech R&D and specialized cancer centers enhancing regional capacity.

Market Challenges

• High Cost of Testing: Advanced molecular assays remain expensive, limiting penetration in lower income APAC markets.
• Regulatory Complexity: Fragmented and evolving approval pathways across different countries delay product launches.
• Skilled Workforce Shortage: Insufficient numbers of trained molecular technologists and bioinformaticians impede broader clinical rollout.
• Data Security & Privacy: Handling of sensitive genomic and patient data raises compliance and cybersecurity concerns.

Table of Contents

Executive Summary

Scope and Definition

1 Molecular Oncology Diagnostics Market: Industry Outlook

• 1.1 Global Incidence and Prevalence of Cancer (by Cancer Type)
  • 1.1.1 Asia-Pacific
• 1.2 Trends: Current and Future Impact Assessment
  • 1.2.1 Increasing Partnerships among Players
  • 1.2.2 Increasing Launch of Innovative Products and Regulatory Approvals in Molecular Oncology Diagnostics Ecosystem
• 1.3 Regulatory Landscape
  • 1.3.1 Legal Requirements and Framework in Asia-Pacific
    • 1.3.1.1 China
    • 1.3.1.2 Japan
• 1.4 Impact of COVID-19 on the Molecular Oncology Diagnostics Market
• 1.5 Liquid Biopsy-Based Cancer Molecular Diagnostics
• 1.6 Laboratory-Developed Test (LDT) vs. In-Vitro Diagnostics (IVD)
• 1.7 Role of Companion Diagnostics in the Molecular Oncology Diagnostics Market
• 1.8 Market Dynamics
  • 1.8.1 Market Drivers
    • 1.8.1.1 Rising Incidence of Cancer Cases
    • 1.8.1.2 Rising Technological Advancements in Molecular Diagnostics
    • 1.8.1.3 Growth in Biomarker Identification and Transformations in Molecular Techniques
    • 1.8.1.4 Growing Demand for Personalized Medicine
  • 1.8.2 Market Challenges
    • 1.8.2.1 Lack of Qualified Professionals
    • 1.8.2.2 High Cost of Molecular Diagnostic Kits and Assays Hindering the Adoption Rate
  • 1.8.3 Market Opportunities
    • 1.8.3.1 Focus on Reimbursement and Medical Coverage for Molecular Oncology Diagnostics
    • 1.8.3.2 Focus on Next-Generation Ultrasensitive Molecular Diagnostics
    • 1.8.3.3 Increasing Growth Opportunities for Molecular Diagnostics Companies in Emerging Economies

2 Molecular Oncology Diagnostics Market: by Region

• 2.1 Regional Summary
• 2.2 Drivers and Restraints
• 2.3 Asia-Pacific
  • 2.3.1 Regional Overview
  • 2.3.2 Driving Factors for Market Growth
  • 2.3.3 Factors Challenging the Market
  • 2.3.4 By Cancer Type
  • 2.3.5 By End User
  • 2.3.6 China
    • 2.3.6.1 By Cancer Type
    • 2.3.6.2 By End User
  • 2.3.7 India
    • 2.3.7.1 By Cancer Type
    • 2.3.7.2 By End User
  • 2.3.8 Japan
    • 2.3.8.1 By Cancer Type By End User
  • 2.3.9 South Korea
    • 2.3.9.1 By Cancer Type
    • 2.3.9.2 By End User
  • 2.3.10 Australia
    • 2.3.10.1 By Cancer Type
    • 2.3.10.2 By End User
  • 2.3.11 Rest-of-Asia-Pacific
    • 2.3.11.1 By Cancer Type
    • 2.3.11.2 By End User
• 2.4 Rest-of-the-World
  • 2.4.1 Regional Overview
  • 2.4.2 Driving Factors for Market Growth
  • 2.4.3 Factors Challenging the Market
  • 2.4.4 By Cancer Type
  • 2.4.5 By End User

3 Molecular Oncology Diagnostics Market - Competitive Benchmarking & Company Profiles

• 3.1 Company Profiles
  • 3.1.1 Sysmex Corporation
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Target Customers/End User
    • 3.1.1.5 Key Personnel
    • 3.1.1.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1 Asia-Pacific Molecular Oncology Diagnostics Market, $Million, 2024, 2028, and 2033
• Figure 2 Molecular Oncology Diagnostics Market (by Region), $Million, 2023, 2027, and 2033
• Figure 3 Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023, 2027, and 2033
• Figure 4 Asia-Pacific Molecular Oncology Diagnostics Market (by End User), $Million, 2023, 2027, and 2033
• Figure 5 Role of Diagnostics in Healthcare
• Figure 6 Cancer Prevalence and Incidence (by Cancer Type), in Million, Asia-Pacific, 2022
• Figure 7 Workflow for Medical Device Regulations
• Figure 8 Technological Advances in Liquid Biopsy Analysis
• Figure 9 List of Some Liquid Biopsy-Based Available Tests Approved by FDA/CE-IVD
• Figure 10 Impact Analysis of Market Navigating Factors, 2022-2033
• Figure 11 Global Distribution of Cases and Deaths (by Cancer Type), 2022
• Figure 12 Global Incidence for Cancer Types, 2018-2022
• Figure 13 China Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 14 India Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 15 Japan Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 16 South Korea Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 17 Australia Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 18 Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 19 Data Triangulation
• Figure 20 Top-Down and Bottom-Up Approach
• Figure 21 Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Key Trends, Impact Analysis
• Table 3: Molecular Oncology Diagnostics Market, Partnerships and Collaborations
• Table 4: Molecular Oncology Diagnostics Market, Product Launches and Regulatory Approvals
• Table 5: Prominent FDA-Approved Companion Diagnostics
• Table 6: Molecular Oncology Diagnostics Market, New Offerings
• Table 7: Biomarkers for Different Cancer Types
• Table 8: Significance of Different Biomarkers in Clinical Outcomes of Various Cancer
• Table 9: Cost of Liquid Biopsy-Based NGS Kits
• Table 10: Molecular Oncology Diagnostics Market, Reimbursement and Medical Coverage
• Table 11: Molecular Oncology Diagnostics Market (by Region), $Million, 2023-2033
• Table 12: Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 13: Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 14: Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 15: Asia-Pacific Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 16: China Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 17: China Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 18: China Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 19: China Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 20: India Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 21: India Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 22: India Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 23: India Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 24: Japan Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 25: Japan Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 26: Japan Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 27: Japan Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 28: South Korea Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 29: South Korea Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 30: South Korea Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 31: South Korea Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 32: Australia Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 33: Australia Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 34: Australia Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 35: Australia Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 36: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 37: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 38: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 39: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033